Susquehanna International Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-363,800
| Closed | -$196K | – | 13813 |
|
|
2024
Q4 | $196K | Buy |
363,800
+268,300
| +281% | +$187K | ﹤0.01% | 10746 |
|
|
2024
Q3 | $168K | Buy |
95,500
+45,200
| +90% | +$63.1K | ﹤0.01% | 10633 |
|
|
2024
Q2 | $58.9K | Sell |
50,300
-103,300
| -67% | -$258K | ﹤0.01% | 11338 |
|
|
2024
Q1 | $1.39M | Sell |
153,600
-3,500
| -2% | -$34K | ﹤0.01% | 6176 |
|
|
2023
Q4 | $1.71M | Buy |
157,100
+31,300
| +25% | +$235K | ﹤0.01% | 5694 |
|
|
2023
Q3 | $1.01M | Sell |
125,800
-23,500
| -16% | -$195K | ﹤0.01% | 6605 |
|
|
2023
Q2 | $1.62M | Sell |
149,300
-65,400
| -30% | -$560K | ﹤0.01% | 5591 |
|
|
2023
Q1 | $1.48M | Buy |
214,700
+27,300
| +15% | +$171K | ﹤0.01% | 5830 |
|
|
2022
Q4 | $746K | Buy |
187,400
+123,300
| +192% | +$606K | ﹤0.01% | 6853 |
|
|
2022
Q3 | $426K | Buy |
64,100
+1,400
| +2% | +$8.62K | ﹤0.01% | 8897 |
|
|
2022
Q2 | $303K | Sell |
62,700
-77,200
| -55% | -$470K | ﹤0.01% | 9548 |
|
|
2022
Q1 | $1.31M | Buy |
139,900
+58,800
| +73% | +$584K | ﹤0.01% | 6470 |
|
|
2021
Q4 | $963K | Sell |
81,100
-4,200
| -5% | -$48.5K | ﹤0.01% | 7404 |
|
|
2021
Q3 | $971K | Sell |
85,300
-74,300
| -47% | -$1.02M | ﹤0.01% | 7635 |
|
|
2021
Q2 | $2.86M | Buy |
159,600
+85,100
| +114% | +$1.37M | ﹤0.01% | 5128 |
|
|
2021
Q1 | $1.15M | Sell |
74,500
-203,400
| -73% | -$2.94M | ﹤0.01% | 7348 |
|
|
2020
Q4 | $3.39M | Buy |
277,900
+40,200
| +17% | +$560K | ﹤0.01% | 4100 |
|
|
2020
Q3 | $3.05M | Buy |
237,700
+191,100
| +410% | +$1.65M | ﹤0.01% | 3826 |
|
|
2020
Q2 | $473K | Buy |
46,600
+22,950
| +97% | +$211K | ﹤0.01% | 7476 |
|
|
2020
Q1 | $192K | Sell |
23,650
-5,450
| -19% | -$47.2K | ﹤0.01% | 8744 |
|
|
2019
Q4 | $251K | Sell |
29,100
-13,975
| -32% | -$78.4K | ﹤0.01% | 8356 |
|
|
2019
Q3 | $265K | Sell |
43,075
-79,275
| -65% | -$641K | ﹤0.01% | 8570 |
|
|
2019
Q2 | $2.03M | Buy |
122,350
+26,100
| +27% | +$453K | ﹤0.01% | 4137 |
|
|
2019
Q1 | $1.61M | Buy |
96,250
+17,900
| +23% | +$258K | ﹤0.01% | 4103 |
|
|
2018
Q4 | $899K | Sell |
78,350
-40,450
| -34% | -$818K | ﹤0.01% | 4887 |
|
|
2018
Q3 | $4.75M | Buy |
118,800
+81,500
| +218% | +$2.32M | ﹤0.01% | 2756 |
|
|
2018
Q2 | $1.05M | Sell |
37,300
-19,625
| -34% | -$435K | ﹤0.01% | 5227 |
|
|
2018
Q1 | $870K | Buy |
56,925
+50,450
| +779% | +$1.2M | ﹤0.01% | 5547 |
|
|
2017
Q4 | $211K | Buy |
+6,475
| New | +$175K | ﹤0.01% | 8195 |
|
Susquehanna International Group's MRNS Position: Q1 2025 in Review
Susquehanna International Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 100,853 shares — an estimated $54K sold.
Susquehanna International Group first reported a position in MRNS in Q3 2016 and held it in 28 quarters. The position peaked at $4.05M in Q1 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Susquehanna International Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Susquehanna International Group sold 100,853 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $54K.
- Susquehanna International Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2016 and held it in 28 quarters.
- Susquehanna International Group's Marinus Pharmaceuticals, Inc position peaked at $4.05M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.